Search research articles
Contact Us
Filters
Showing results (11-20 of 133) with videos related to
Page
of 14
Sort By:
Frontiers in Oncology
|
June 20, 2022
The Values of Systemic Immune-Inflammation Index and Neutrophil-Lymphocyte Ratio in Predicting Biochemical Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy
Shuo Wang, Xiao Yang, Ziyi Yu, et al.
Zhonghua Yi Xue Za Zhi
|
December 17, 2014
[Impact of sequential targeted therapy on progression-free survival in metastatic renal cell carcinoma]
Lu Si, Xue Bai, Lili Mao, et al.
Acta Pharmaceutica Sinica. B
|
September 3, 2020
Evaluation of <sup>124</sup>I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice
Haifeng Huang, Hua Zhu, Quan Xie, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
October 15, 2015
[A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule]
Chuanliang Cui, Siming Li, Zhihong Chi, et al.
Scientific Reports
|
January 6, 2017
Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma
Jie Dai, Shan Wu, Yan Kong, et al.
Bladder (San Francisco, Calif.)
|
September 23, 2024
A narrative review of advances in the management of urothelial cancer: Diagnostics and treatments
Shaoxu Wu, Shengwei Xiong, Juan Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2013
Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma
Bin Lian, Lu Si, Chuanliang Cui, et al.
The Journal of Investigative Dermatology
|
September 27, 2021
EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma
Tianxiao Xu, Jie Dai, Lirui Tang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 27, 2011
Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort
Lu Si, Yan Kong, Xiaowei Xu, et al.
The Oncologist
|
February 17, 2026
Toripalimab in Patients with Previously Treated Advanced Upper Tract Urothelial Carcinoma: A Subgroup Analysis of the Phase II POLARIS-03 Trial
Jinchang Wei, Ruiyun Zhang, Juan Li, et al.
Page
of 14
Search research articles
Search
Showing results (11-20 of 133) with videos related to
Sort By:
Page
of 14
Frontiers in Oncology
|
June 20, 2022
The Values of Systemic Immune-Inflammation Index and Neutrophil-Lymphocyte Ratio in Predicting Biochemical Recurrence in Patients With Localized Prostate Cancer After Radical Prostatectomy
Shuo Wang, Xiao Yang, Ziyi Yu, et al.
Zhonghua Yi Xue Za Zhi
|
December 17, 2014
[Impact of sequential targeted therapy on progression-free survival in metastatic renal cell carcinoma]
Lu Si, Xue Bai, Lili Mao, et al.
Acta Pharmaceutica Sinica. B
|
September 3, 2020
Evaluation of <sup>124</sup>I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice
Haifeng Huang, Hua Zhu, Quan Xie, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|
October 15, 2015
[A pilot study of sunitinib as first-line therapy for metastatic renal cell carcinoma on a 2 weeks on/1 week off intermittent dosing schedule]
Chuanliang Cui, Siming Li, Zhihong Chi, et al.
Scientific Reports
|
January 6, 2017
Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the mTOR Inhibitor Everolimus against Melanoma
Jie Dai, Shan Wu, Yan Kong, et al.
Bladder (San Francisco, Calif.)
|
September 23, 2024
A narrative review of advances in the management of urothelial cancer: Diagnostics and treatments
Shaoxu Wu, Shengwei Xiong, Juan Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 9, 2013
Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma
Bin Lian, Lu Si, Chuanliang Cui, et al.
The Journal of Investigative Dermatology
|
September 27, 2021
EZH2 Inhibitor Enhances the STING Agonist‒Induced Antitumor Immunity in Melanoma
Tianxiao Xu, Jie Dai, Lirui Tang, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 27, 2011
Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort
Lu Si, Yan Kong, Xiaowei Xu, et al.
The Oncologist
|
February 17, 2026
Toripalimab in Patients with Previously Treated Advanced Upper Tract Urothelial Carcinoma: A Subgroup Analysis of the Phase II POLARIS-03 Trial
Jinchang Wei, Ruiyun Zhang, Juan Li, et al.
Page
of 14